AVO.L Regulatory News (AVO)

26 April 2013

ADVANCED ONCOTHERAPY Plc

("Advanced Oncotherapy" or "the Company")

Director Appointment

Further to the Issue of Equity announcement released on 24 April 2013, Advanced Oncotherapy is pleased to announce the appointment of Michael Bradfield as a Non-Executive director of the Company. This appointment follows Mr Bradfield's £1m investment in the Company ("the Placing").

Michael Bradfield, aged 61, has over 30 years experience of Direct Marketing and the Insurance Industry as founder and CEO of Hospital Plan Insurance Services (HPIS), a direct seller of low cost Health, Accident and Life Insurance. Michael has a law degree from LSE, was the youngest full Member of Lloyds of London and a computer application programmer since the late 1960's, specialising in insurance based administration and correspondence systems and database marketing. HPIS was sold to AIG in 2000 when it expanded into Europe. Since 2004 he has been an active investment manager, especially in technology based companies and sustainable industries.

There is no further information required to be disclosed under paragraph (g) of Schedule 2 of the AIM Rules.

Following the admission of the Placing shares, Mr. Bradfield will hold 100,000,000 ordinary shares, representing approximately 27.8 per cent. of the issued share capital of Advanced Oncotherapy.

Commenting on the appointment, Michael Sinclair, Chief Executive said "I am delighted to welcome Michael to our board. His experience will undoubtedly help us to grow the company and he has already demonstrated his enthusiasm through the substantial investment he has made in Advanced Oncotherapy."

For further information, please visit www.advancedoncotherapy.comor contact: